Haemodialysis and Haemofiltration: Dosing
Use of Fragmin® for the prevention of clotting in the extracorporeal circulation during haemodialysis
Reduce the risk of venous thromboembolism (VTE) in patients undergoing dialysis1
Prevention of clotting in the extracorporeal circulation during haemodialysis or haemofiltration, in patients with chronic renal insufficiency or acute renal failure1
Dosage for haemodialysis/haemofiltration1**
** Fragmin® does NOT routinely require dose adjustment but caution should be exercised in patients where there is an increased risk of bleeding complications, e.g. in severe renal failure. Monitoring of anti-Xa levels should be considered in patients with renal failure.
1. Fragmin SmPC [Haemodialysis/Haemofiltration (10,000 IU/1 ml & 10,000 IU/4 ml ampoules)]. Available at: https://www.medicines.org.uk/emc/product/4251 and https://www.medicines.org.uk/emc/product/4244
*Including, but not limited to: congestive cardiac failure (NYHA class III or IV), acute respiratory failure or acute infection, who also have a predisposing risk factor for VTE such as age over 75 years, obesity, cancer or previous history of VTE.~
†In patients with chronic renal insufficiency or acute renal failure.
PP-FRA-GBR-0166. June 2019